The US electrophysiology (EP) diagnostic catheter market, particularly the segment for advanced EP diagnostic catheters, is projected to experience a robust compound annual growth rate (CAGR) of 10% in market value from 2024 to 2033, forecasts GlobalData, a leading data and analytics company.

GlobalData’s report, “Electrophysiology Diagnostic Catheters Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033,” reveals that the US EP catheter market growth is driven by increasing physician adoption, improved reimbursement policies, rising patient awareness, and the launch of next-generation device innovations, highlighting the evolving landscape of cardiac care solutions.

EP diagnostic catheters, used for intracardiac sensing, recording, stimulation, and mapping, are integral to diagnosing and managing arrhythmias. Arrhythmias, characterized by irregular heart rhythms, are increasingly prevalent in the US due to an aging population and lifestyle-related factors such as hypertension, diabetes, obesity, and physical inactivity.

The US market, the largest globally for EP diagnostic catheters, benefits from a higher number of facilities and specialists compared to other countries. Advanced EP diagnostic catheters, while costlier, provide superior diagnostic capabilities, supporting their adoption despite price concerns.

Thomas Fleming, Medical Analyst at GlobalData, comments: “Market drivers include the growing incidence of arrhythmias, increasing adoption of minimally invasive procedures, and the high effectiveness of EP diagnostic and ablation techniques. Additionally, improvements in catheter accuracy have made EP procedures more reliable, leading to better patient outcomes and reduced recurrence rates.”

Despite the promising growth trajectory, the market faces notable challenges. The high cost of advanced EP diagnostic catheters could hinder accessibility, particularly in cost-sensitive healthcare settings.

Additionally, the growing adoption of reprocessed catheters—priced at nearly 50% less than new devices—creates a significant competitive hurdle for manufacturers. With reprocessing permitted in certain markets, it continues to impact potential revenue streams for original equipment manufacturers.

Fleming concludes: “Overall, the US EP diagnostic catheter market’s growth will be bolstered by the advances in technology and procedure effectiveness. Continued innovations, coupled with cost-effective solutions, are likely to address the market barriers and sustain long-term expansion.”